AI
DICE

Atom Investors’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Atom Investors’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-39,100
Closed -$990K – 354
2021
Q4 		$990K Buy
+39,100
New +$1.15M 0.17% 109

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Atom Investors's DICE Position: Q1 2022 in Review

Atom Investors sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q1 2022, closing a stake of 39,100 shares — an estimated $990K sold.

Atom Investors first reported a position in DICE in Q4 2021 and held it in 1 quarter. The position peaked at $990K in Q4 2021. 76 funds tracked by Wall St. Rank hold DICE as of Q1 2022.

  • Atom Investors reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Atom Investors sold 39,100 DICE Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $990K.
  • Atom Investors first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Atom Investors's DICE Therapeutics, Inc. Common Stock position peaked at $990K in Q4 2021.
  • 76 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Atom Investors's 13F filing for Q1 2022, filed 16 May 2022.